Academíc Sciences

#### **International Journal of Pharmacy and Pharmaceutical Sciences**

ISSN- 0975-1491

Vol 5, Issue 2, 2013

**Research Article** 

# DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR SIMULTANEOUS DETERMINATION OF TELMISARTAN AND CHLORTHALIDONE IN BULK AND PHARMACEUTICAL DOSAGE FORM

## KRENY E. PARMAR\*, R.S MEHTA, NIKITA D. PATEL, KRENY E. PARMAR \*

\*Snehsagar Society, St. Xavier's road, Anand 388001, Gujarat, India, A. R. College of pharmacy and G. H. Patel institute of Pharmacy, Vallabh Vidyanagar 388120, Anand, Gujarat, India, Arati society, Ajay Tenament-5, Mahadevnagar, Vastral road, Ahmedabad-382418, Gujarat, India. Email: kreny.25@gmail.com

#### Received: 31 Jan 2013, Revised and Accepted: 09 Mar 2013

#### ABSTRACT

A simple, accurate and precise densitometric method for the simultaneous estimation of Telmisartan and Chlorthalidone in Bulk and Pharmaceutical Dosage form has been developed and validated. Separation of drugs was carried out using Acetonitrile: Toluene: Glacial acetic acid (7.5: 2.5: 0.05 v/v/v) as mobile phase on precoated Silica Gel 60F254 plates. The densitometric evaluation of spots was carried out at 242 nm. The R<sub>f</sub> value for Telmisartan and Chlorthalidone were found to be  $0.26 \pm 0.02$  and  $0.67 \pm 0.02$ , respectively. The method was validated with respect to linearity, accuracy, precision and robustness as per the International Conference on Harmonisation (ICH) guidelines. The drug response with respect to peak area was linear over the concentration range 400-2400 ng/spot (n=6) and 125-750 ng/spot (n=6) for Telmisartan and Chlorthalidone . The percentage recovery of Telmisartan and Chlorthalidone was found to be 100.03 and 100.026  $\pm$  0.15 ng/spot and 15.6 ng/spot for Chlorthalidone . The percentage recovery of Telmisartan and Chlorthalidone was found to be 100.03 and 100.026 sufficiently precise. The method can be successfully employed for the simultaneous determination of Telmisartan and Chlorthalidone in pharmaceutical formulations.

Keywords: Telmisartan, Chlorthalidone, HPTLC, Simultaneous determination, Validation.

#### INTRODUCTION

Telmisartan (TEL) is chemically 4'-[[4-methyl-6-(1-methyl-2-benzimidazolyl]-2-propyl-1-benzimidazolyl]methyl]-2-

biphenylcarboxylic acid (Fig. 1) is a Antihypertensive drug [1-7]. It is an Angiotensin II receptor antagonist. It is official in Indian Pharmacopoeia (IP), British Pharmacopoeia (BP) and U.S. Pharmacopoeia(USP). It is estimated by Liquid Chromatography as per IP and Potentiometric titration as per BP and USP [5-7].Literature review reveals that HPLC[9-13], UV[14-16] spectrophotometric and HPTLC[17-23]methods has been reported for estimation of TEL in pharmaceutical dosage forms. Chlorthalidone (CHL) is chemically (RS)-2-chloro-5-(1-hydroxy-3oxoisoindolin-l-yl)benzenesulphonamide (Fig.2).It is a diuretic drug used to treat hypertension[1-7].It is official in IP, BP and USP and estimated by potentiometric titration as per IP and Liquid Chromatography as per BP and USP[5-7]. Literature review also reveals that HPLC [24-27], UV [28] spectrophotometric methods has been reported for the estimation of CHL in pharmaceutical dosage forms. Literature survey does not reveal any HPTLC method for simultaneous determination of TEL and CHL in Pharmaceutical dosage form. The present developed HPTLC method is simple, precise and accurate for simultaneous determination of both drugs in their Pharmaceutical Dosage forms as per International Conference on Harmonization (ICH) guidelines[8].



#### Fig. 1: Structure of Telmisartan (TEL)



Fig. 2: Structure of Chlorthalidone (CHL)

#### MATERIALS AND METHODS

#### **Chemicals and Reagents**

Pure drug samples of Telmisartan & Chlorthalidone were provided as a gift sample by Alembic Limited, Vadodara,Gujarat, India. Commercial pharmaceutical tablets **ERITEL-CH40** (Eris Lifesciences Pvt. Ltd, Ahmedabad, Gujarat, India) was procured from local pharmacy. Acetonitrile, Toluene, Methanol and Glacial acetic acid of AR Grade. Acetonitrile was obtained from S D Fine Chem Limited, Mumbai, Maharastra, India and all other chemicals were obtained from Allied Chemical Corporation, Vadodara, Gujarat, India.

#### Instrumentation and Chromatographic conditions

The HPTLC system (Camag, Muttenz, Switzerland) consisted of Linomat V autosprayer connected to a nitrogen cylinder, a twin trough chamber  $(10 \times 10 \text{ cm})$ , a derivatization chamber, and a plate heater. Pre-coated silica gel 60 F254 TLC plates (10 × 10 cm, layer thickness 0.2 mm (E. MerckKGaA, Darmstadt, Germany) was used as stationary phase. TLC plates were pre-washed with methanol and activated at 80°C for 5 min prior to sample application. The standard and formulation samples of TEL and CHL in mixture were spotted on Precoated TLC plates in the form of narrow bands of lengths 6 mm. Samples were applied under continuous drying stream of nitrogen gas at constant application rate of 150 nL/s. The mobile phase consists of Acetonitrile: Toluene: Glacial acetic acid (7.5:2.5:0.05 v/v/v). Linear ascending development was carried out in twin trough chamber (10 x 10 cm). The optimized chamber saturation time for mobile phase was 15 min, at ambient temperature; the length of chromatogram run was 7 cm. Densitometric scanning was performed on CAMAG TLC scanner 3 in Absorbance/Reflectance mode, operated by winCATS 1.3.4 planar chromatography software. The spots were analyzed at a wavelength of 242 nm. The slit dimensions used in the analysis were length and width of 5 mm and 0.45 mm, respectively, with a scanning rate of 20 mm/s. The parameters were selected as recommended by the CAMAG TLC scanner 3 manual. Evaluation was performed using linear regression analysis of peak areas.

# Preparation of stock, working standard solutions and calibration curves

Accurately weighed Telmisartan (10 mg) was transferred to 10 ml volumetric flask, dissolved in and diluted with methanol up to the

mark (1000 µg/ml). For preparation of CHL stock solution, accurately weighed Chlorthalidone (10 mg) was transferred to 10 ml volumetric flask, dissolved in and diluted with methanol up to the mark (1000 µg/ml). For preparation of working standard solution, 4 ml of stock solution of TEL (1000 µg/ml) and 1.25 ml of stock solution of CHL(1000µg/ml) were transferred to 10 ml volumetric flask and diluted with methanol up to the mark to obtain final concentration containing 400 µg/ml of TEL and 125 µg/ml of CHL. Calibration was done by applying mixture of standard solutions ranging from 1.0 – 6.0 µl by Hamilton syringe with the help of Linomat V autosprayer on TLC plate that gave concentration 400-2400 ng/spot for TEL and 125-750 ng/spot for CHL, respectively. Each concentration was spotted six times on TLC plates. From the developed plates calibration curve was plotted as peak areas versus corresponding concentrations (Fig. 5 and 6).

#### Analysis of TEL and CHL in marketed Tablet Formulation

To determine the content of TEL and CHL simultaneously in conventional tablets (Eritel- CH40 label claim 40 mg TEL and 12.5 mg CHL); twenty tablets were accurately weighed, average weight determined and ground to fine powder. A quantity of powder equivalent to 40 mg (TEL) and 12.5 mg (CHL) was transferred into 100 ml volumetric flask containing 50 ml methanol, sonicated for 30 min and diluted to mark with same solvent to obtain 0.4 mg/ml of TEL and 0.125 mg/ml of CHL. The resulting solution was filtered using 0.45  $\mu$ m filter (Millifilter, MA). So, Resultant solution was found to contain 400  $\mu$ g/ml (400ng/ $\mu$ l) Telmisartan and 125 $\mu$ g/ml (125 ng/ $\mu$ l) Chlorthalidone. 3  $\mu$ l of this solution was applied on TLC plate followed by development and scanning at 242 nm. The analysis was repeated for three times.

#### **Development and Validation of HPTLC Method**

#### Linearity

For the linearity study the 1-6  $\mu$ l from the working standard solution containing 400 ng/spot of TEL and 125 ng/spot of CHL was injected. So, linearity responses for TEL and CHL were assessed in the concentration range 400-2400 ng/spot and 125-750 ng/spot, of working standard solutions, respectively.

#### Precision

Precision of the method was determined in the terms of intra-day and inter-day variation (%RSD). Intra-day precision (%RSD) was assessed by analyzing standard drug solutions within the calibration range, three times on the same day. Inter-day precision (%RSD) was assessed by analyzing drug solutions within the calibration range on three different days over a period of 7 days.

#### Accuracy

To the pre-analyzed sample a known amount of standard solution of pure drug (TEL and CHL) was spiked at three different levels (80%,

100% and 120%). These solutions were subjected to re-analysis by the proposed method.

#### Sensitivity

The sensitivity of measurement of TEL and CHL by the use of proposed method was estimated in terms of Limit of Detection (LOD) and Limit of Quantitation (LOQ). The LOD and LOQ were calculated by equation. Based on the standard deviation of the response and the slope, LOD and LOQ were estimated using the formulae:

LOD=  $3.3 \sigma/S$ 

Where,  $\sigma$  = the standard deviation of the response

S = the slope of the calibration curve

 $LOQ = 10 \sigma/S$ 

Where,  $\sigma$  = the standard deviation of the response

S = the slope of the calibration curve

LOD and LOQ were determined from the standard deviations of the responses for six replicate determinations.

#### Specificity

Specificity of the method was ascertained by analyzing standard drug and sample. The mobile phase resolved both the drugs very efficiently as shown in Fig. 7. The spot for TEL and CHL was confirmed by comparing the  $R_f$  and spectra of the spot with that of standard. The wavelength 242 nm for detecting peak purity of TEL and CHL was assessed by comparing the spectra at three different levels, i.e., peak start (S), peak apex (M) and peak end (E) positions of the spot.

#### Repeatability

Repeatability of sample application was assessed by spotting  $4\mu L$  (1600 ng/spot of TEL and 500 ng/spot of CHL) of drug solution six times on a TLC, followed by development of plate and recording the peak area for six spots.

#### **RESULTS AND DISCUSSION**

The TLC procedure was optimized for simultaneous determination of TEL and CHL. The mobile phase Acetonitrile: Toluene: Glacial acetic acid (7.5:2.5:0.05v/v/v) resulted in good resolution and sharp and symmetrical peaks of  $R_f 0.26 \pm 0.02$  for TEL and  $0.67 \pm 0.02$  for CHL. It was observed that pre-washing of TLC plates with methanol (followed by drying and activation) and pre-saturation of TLC chamber with mobile phase for 15 min (optimum chamber saturation time) ensured good reproducibility and peak shape of both the drugs. (Fig. 3)



Fig. 3: HPTLC Chromatogram of Standard TEL and CHL in mixture

#### Linearity

Linear regression data for the calibration plots revealed good linear relationships between area and concentration over the ranges 400-2400 ng/spot for TEL and 125-750 ng/spot for CHL. The linear equations for the calibration plots were y = 3.377x+1356 and y = 7.726x+201.3 with Regression (r<sup>2</sup>) being 0.995 and 0.995 for TEL and CHL, respectively (Fig. 4,5,6) (Table 1, 2 and 3).

#### Precision

The precision of the method was expressed as relative standard deviation (RSD %). The %R.S.D. values for intra-day precision study and inter-day study listed in (Table 4 and 5) were<1.0%, confirming that the method was sufficiently precise.

#### Accuracy

When the method was used for accuracy and subsequent analysis of both the drugs from the pharmaceutical dosage form, and spiked with 80, 100, and 120% of additional pure drug, the recovery was found to be %99.95-100.11 for TEL and %99.81-100.41 for CHL (Table 6 and 7).

#### Sensitivity

The LOD and LOQ were calculated by equation. The LOD and LOQ values were 9.049 and 27.422 ng/spot for TEL and 5.147 and 15.598 ng/spot for CHL.

#### Specificity

The peak purity of TEL and CHL were assessed by comparing their respective spectra at peak start, apex and peak end positions of the spot i.e., r (S, M) =0.9996 and r (M, E) =0.9990 for TEL and r (S, M) =0.9984 and r (M, E) =0.9989 for CHL. Good match was obtained between standard and sample spectra of TEL and CHL respectively. (Fig. 7)

#### Repeatability

The % RSD for peak area values of TEL and CHL were found to be 0.1206 and 0.3388 respectively, as given in Table 8.



#### Fig. 4: 3D Representation of Densitogram for Calibration curve of TEL and CHL

#### Table 1: Result of Calibration readings for TEL

| Concentration (ng/spot) | R <sub>f</sub> | Area Mean (n=6) ± SD | %RSD   |
|-------------------------|----------------|----------------------|--------|
| 400                     | 0.25           | 2564.967±6.729       | 0.2623 |
| 800                     | 0.26           | 3396.017±11.673      | 0.2921 |
| 1200                    | 0.26           | 5574.767±10.142      | 0.1819 |
| 1600                    | 0.26           | 6997.55±8.434        | 0.1205 |
| 2000                    | 0.27           | 8108.433±9.03        | 0.1113 |
| 2400                    | 0.27           | 9270.767±9.559       | 0.1031 |

#### **Table 2: Result of Calibration readings for CHL**

| Concentration (ng/spot) | R <sub>f</sub> | Area Mean (n=6) ± SD | %RSD   |
|-------------------------|----------------|----------------------|--------|
| 125                     | 0.66           | 991.5667±10.539      | 1.0629 |
| 250                     | 0.66           | 2199.7±12.121        | 0.551  |
| 375                     | 0.67           | 3249.483±12.844      | 0.3952 |
| 500                     | 0.67           | 4143.667±14.057      | 0.3392 |
| 625                     | 0.67           | 5029.783±11.72       | 0.233  |
| 750                     | 0.67           | 5875.1±11.027        | 0.1877 |

## Table 3: Statistical Data of TEL and CHL

| Parameters                                      | Results          |                   |  |
|---|------------------|-------------------|--|
|   | TEL              | CHL               |  |
| Linear Range(ng/spot)                           | 400-2400         | 125-750           |  |
| Slope   | 3.377            | 7.726             |  |
| Intercept                                       | 1356             | 201.3             |  |
| Std. Deviation of Slope                         | 0.00608          | 0.01269           |  |
| Std. Deviation of Intercept                     | 9.3594           | 10.7742           |  |
| Limit of Detection(ng/spot)                     | 9.05             | 5.15              |  |
| Limit of Quantitation(ng/spot)                  | 27.42            | 15.6              |  |
| Regression Equation                             | y =3.377 x +1356 | y =7.726 x +201.3 |  |
| Co-Relation Co-Efficient (r)                    | 0.99749          | 0.99749           |  |
| Co-Efficient of Determination (r <sup>2</sup> ) | 0.995            | 0.995             |  |



Fig. 5: Calibration curve of TEL in Methanol at 242 nm



Fig. 6: Calibration curve of CHL in Methanol at 242 nm

| Table 4: Int | tra-Day and Ir | iter-Day stud | ly of TEL |
|--------------|----------------|---------------|-----------|

| Concentration (ng/spot) | Intra-Day Area Mean (n=3) ± SD | %RSD   | Inter-Day Area Mean (n=3) ± SD | %RSD   |
|-------------------------|--------------------------------|--------|--------------------------------|--------|
| 800                     | 3995.1±3.305                   | 0.0827 | 3994.73±2.515                  | 0.0629 |
| 1200                    | 5575.166±3.625                 | 0.065  | 5575.966±3.564                 | 0.0639 |
| 1600                    | 6999.567±3.711                 | 0.053  | 6998.33±3.763                  | 0.0537 |

## Table 5: Intra-Day and Inter-Day study of CHL

| Concentration (ng/spot) | Intra-Day Area Mean (n=3) ± SD | %RSD   | Inter-Day Area Mean (n=3) ± SD | %RSD   |
|-------------------------|--------------------------------|--------|--------------------------------|--------|
| 250                     | 2200.233±3.372                 | 0.1533 | 2198.5±4.782                   | 0.2175 |
| 375                     | 3249.367±2.369                 | 0.0729 | 3250.033±3.493                 | 0.1075 |
| 500                     | 4144.633±3.004                 | 0.0724 | 4148.367±3.296                 | 0.0795 |

| Table 6: Determination | of Accuracy | for | TEI |
|------------------------|-------------|-----|-----|
|------------------------|-------------|-----|-----|

| Concentration of<br>Sample Taken (ng/spot) | Concentration of Pure | Total Concentration (ng/spot) | Mean Total Concentration | %Recovery | %RSD   |
|--|-----------------------|-------------------------------|--------------------------|-----------|--------|
|  | All Spiket (lig/spot) | 1440                          | 1420.00                  |           | 0.2007 |
| 800  | 640                   | 1440                          | 1439.69                  | 99.95     | 0.2087 |
|  | 800                   | 1600                          | 1600.85                  | 100.11    | 0.2441 |
|  | 960                   | 1760                          | 1760.25                  | 100.03    | 0.2268 |
| Average                                    |                       |                               |                          | 100.03    |        |

| Concentration of<br>Sample Taken<br>(ng/spot) | Concentration of Pure<br>API spiked (ng/spot) | Total Concentration<br>(ng/spot) | Mean Total Concentration<br>Found (n=3) (ng/spot) | %Recovery Mean<br>(n=3) | %RSD   |
|---|---|----------------------------------|---|-------------------------|--------|
| 250   | 200   | 450                              | 449.6159  | 99.81                   | 0.7528 |
|   | 250   | 500                              | 501.0267  | 100.41                  | 0.6213 |
|   | 300   | 550                              | 549.5944  | 99.86                   | 0.7346 |
| Average                                       |   |                                  |   | 100.026                 |        |

## Table 7: Determination of Accuracy for CHL



Fig. 7: UV Absorption (Reflectance Mode) of the corresponding spots for TEL and CHL

## Table 8: Repeatability study of TEL and CHL

| Concentration | TEL (1600ng/spot) | CHL (500ng/spot) |
|---------------|-------------------|------------------|
| Area          | 7009              | 4144.9           |
|               | 6991.7            | 4135.7           |
|               | 7001.1            | 4159.3           |
|               | 6985.2            | 4161.5           |
|               | 7002.4            | 4129.1           |
|               | 6996.1            | 4131.6           |
| Mean          | 6997.583          | 4143.683         |
| ± SD          | 8.439             | 14.037           |
| %RSD          | 0.1206            | 0.3388           |

## Table 9: Assay Result of Marketed Formulation

| Parameters                       | Eritel CH-40 TAB |            |  |
|----------------------------------|------------------|------------|--|
|                                  | TEL              | CHL        |  |
| Actual Concentration (ng/spot)   | 1200             | 375        |  |
| Concentration Obtained (ng/spot) | 1204.56          | 374.44     |  |
| %Purity                          | 100.38           | 99.85      |  |
| %RSD                             | 0.5897           | 0.896      |  |
| Limit[5]                         | 90-110           | 92.5-107.5 |  |

## **Table 10: Validation Parameters**

| Summary of Validation Parameters |           |           |  |  |  |
|----------------------------------|-----------|-----------|--|--|--|
|                                  | TEL       | CHL       |  |  |  |
| Recovery (%)                     | 100.03    | 100.026   |  |  |  |
| Repeatability (%RSD)             | 0.1206    | 0.3388    |  |  |  |
| Precision (CV)                   |           |           |  |  |  |
| Intra-day (n=3)                  | 0.000669  | 0.000996  |  |  |  |
| Inter-day (n=3)                  | 0.000602  | 0.00135   |  |  |  |
| Specificity                      | Specific  | Specific  |  |  |  |
| Selectivity                      | Selective | Selective |  |  |  |

#### Analysis of TEL and CHL in marketed formulation

When the Eritel- CH40 tablets were analyzed, TEL and CHL gave sharp and well defined peaks at  $R_f$  0.26±0.02 and 0.67±0.02, respectively, when scanned at 242 nm. The results in Table 9 indicate that there was no interference from the excipients commonly present in the tablet formulation. The % purity was %100.38 for TEL and %99.85 for CHL.

#### CONCLUSION

The developed HPTLC method is simple, precise, accurate and reproducible and can be used for simultaneous determination of TEL and CHL in pharmaceutical dosage forms. The method was validated as per International Conference on Harmonization (ICH) guidelines.

#### ACKNOWLEDGEMENT

Authors are thankful to Alembic Limited, Vadodara, Gujarat, India for gratis sample of Telmisartan & Chlorthalidone as well as Sophisticated Instrumentation Center for Applied Research & Testing (SICART), Vallabh Vidyanagar, Gujarat, India, for providing facilities to complete this work successfully.

#### REFERENCES

- 1. Maryadele J. O' Neil. The Merck Index. 14th ed. New Jersey: Merck Research Laboratories, Division of Merck and Co., Inc. Whitehouse station; 2006. 2193,9131.
- Sean C Sweetman. MARTINDALE: The Complete Drug Reference. 36<sup>th</sup> edn. Great Britain: Pharmaceutical Press; 2009. 1243,1409.
- 3. Drug bank: Temisartan (DB00966), Open drug data and drug Target database http://www.drugbank.ca/drugs/ DB00966
- Drug bank: Chlorthalidone (DB00310), Open drug data and drug Target database http://www.drugbank.ca/drugs/ DB00310
- Indian Pharmacopoeia, Ministry of Health & Family Welfare, Vol-II & III. 6<sup>th</sup> edn. Indian Pharmacopoeial commission, Ghaziabad, India; 2010. p.1076-77,2186-88
- British pharmacopoeia- Vol-I & II. 6<sup>th</sup>Edn .The stationary office, London; 2010. p. 484-85, 2042-44.
- United States Pharmacopoeia-34 and National Formulary-29 Vol. II & III. The United States Pharmacopoeial Convention, Rockville, MD, USA; 2011.p. 2321-22,4357-58
- ICH, Q2B(R1) Validation of Analytical Procedure Methodology, International Conference on Harmonization, IFPMA, Geneva, Switzerland.www.ich.org/fileadmin/Public.../ICH.../Q2\_R1\_Gu ideline.pdf
- 9. Kumar GV, Murthy TEGK, Rao KRS Validated rp-hplc method for the estimation of telmisartan in serum samples. International Journal Of Research In Pharmacy And Chemistry 2011; 1(3):703-706.
- 10. Sujana K, GowriSankar D, BalaSouri O, Swathi RG Stability indicating rp hplc method for the determination of telmisartan in pure and pharmaceutical formulation. International Journal of Pharmacy and Pharmaceutical Sciences 2011; 3(2):164-167.
- 11. Jawla S, Jeyalakshmi K, Krishnamurthy T, Kumar Y Development and Validation of Simultaneous HPLC method for Estimation of Telmisartan and Ramipril in Pharmaceutical Formulations. International Journal of PharmTech Research 2010; 2(2): 1625-1633.
- 12. Rao AL, Varma D, Dinda SC Stability indicating rp-hplc method for simultaneous Determination of telmisartan and hydrochlorothiazide in Pharmaceutical dosage form. International Journal Of Pharmaceutical, Chemical And Biological Sciences 2012; 2(3): 382-391.
- 13. Kayal SD, Khan FA, Tated AG, Bakal RL ,Chandekar AV Method development and validation for the simultaneous determination of amlodipine besylate and telmisartan in tablet dosage form by rp- hplc. International journal of

Pharmaceutical research and development 2011; 3(5): 144 – 153.

- 14. Tatane S Development of UV Spectrophotometric Method of Telmisartan in Tablet Formulation. Journal of Advances in Pharmacy and Healthcare Research 2011;1:23-26.
- 15. Patel PB, Marolia BP, Shah SA, Shah DR Second order derivative spectrophotometric method for simultaneous estimation of telmisartan and metoprolol in tablet dosage form. International Research Journal of Pharmacy 2012;3(5):259-62
- 16. Shah BB, Patel BB, Gohil KN, Patel PM Difference Spectrophotometric Method Development and Validation For Simultaneous Estimation of Rosuvastatin Calcium and Telmisartan in Bulk and Combined Dosage Form. International Journal of Research in Pharmacy and Science 2012; 2(2): 106-114.
- 17. Smita VL Stability-indicating hptlc method for telmisartan in the presence of degradation products, its process related impurity and identification of acid degradation product. Inventi Impact: Pharm Analysis & Quality Assurance 2011;11:194.
- Shah NJ, Suhagia BN, Shah RR, Shah PB Development and validation of a HPTLC method for the simultaneous estimation of telmisartan and hydrochlorothiazide in tablet dosage form. International journal of Pharmaceutical science 2007; 69(2): 202-205.
- Patel VA, Patel PG, Chaudhary BG, Rajgor NB, Rathi SG Development and Validation of HPTLC Method for the Simultaneous Estimation of Telmisartan and Ramipril in Combined Dosage Form. International Journal on Pharmaceutical and Biological Research 2010; 1(1):18-24.
- Patil UP, Gandhi SV, Sengar MR, Rajmane VS A validated densitometric method for analysis of telmisartan and atorvastatin calcium in fixed dose combination. Journal Of The Chilean Chemical Society 2010; 55(1):94-96.
- 21. Deshpande P, Gandhi S, Bhavnani V, Pawar P High performance thin layer chromatographic determination of Cilnidipin and Telmisartan in combined Tablet dosage form. International Research Journal Of Pharmacy 2012; 3(6):219-222
- 22. Vekariya NR, Patel MB, Patel GF, Dholakiya RB Development and validation of TLC-densitometry method for simultaneous determination of telmisartan and amlodipine besylate in bulk and tablets. Journal of young Pharmacist 2009; 1 (3): 259-263.
- 23. Lakshmi S, Lakshmi KS, Pal K Stability indicating HPTLC method for simultaneous determination of Telmisartan and Ramipril in tablets. International journal of Pharmacy and Pharmaceutical science 2010;2(4):127-129.
- 24. Singh B, Patel DK, Ghosh SK A reversed-phase high performance liquid chromatographic Method for chlorthalidone determination Pharmaceutical of in formulation. International Journal of Pharmacy and Pharmaceutical Sciences 2009;1(2):24-27.
- Madhu Babu K, Bikshal Babu K Reverse phase-hplc method development and validation for the Simultaneous estimation of Azilsartan medoxomil and Chlortalidone in pharmaceutical dosage forms. Journal of Atoms and Molecules 2012; 2(1): 117– 126.
- Elgawish M, Mustafa S Simple and rapid HPLC method for simultaneous determination of Atenolol and Chlorthalidone in spiked human plasma. Soudi Pharmaceutical Journal 2011; 19(1):43-49.
- 27. Mhaske RA, Sahasrabudhe S, Mhaske AA Rp-hplc method for simultaneous determination of irbesartan, losartan, hydrochlorothiazide and chlorthalidone–application to commercially available drug products. International Journal of Pharmaceutical Science and Research 2012;3(4):1116-1123.
- Nivedita G, Akiful HM, Prashanth Kumar K, Pradeep Kumar T, Hasan Amrohi S,Diwan Prakash V et al. Simultaneous Estimation of Atenolol and Chlorthalidone as Bulk and In Tablet Dosage Form Using Uv- Spectrophotometry. Journal of Pharmacy and Biological Sciences 2012; 1(4): 20-23.